Discover an ADT in a different class3
DEGARELIX FERRING is a different class of ADT1
LHRH agonists that overstimulate gonadotrophin releasing hormone (GnRH) receptors and rely on a negative feedback to achieve testosterone suppression, but may cause an initial clinical flare.
DEGARELIX FERRING, a GnRH antagonist that blocks GnRH receptors directly, enabling rapid testosterone suppression.
DEGARELIX FERRING is significantly more effective in controlling disease-related symptoms vs. LHRH agonists8
Urinary-tract problems
Urinary-associated problems, e.g. obstructive uropathy leading to persistent infections and LUTS
Bone and back pain
As a result of arthralgia, or eventually bone metastases, which can lead to fractures and spinal cord compression
What do patients think about DEGARELIX FERRING?
Monthly DEGARELIX FERRING administration was considered satisfactory by 82% of patients (173/211) at 6 months11*
Satisfaction was sustained during the maintenance phase, with patient satisfaction rate increased to 83.6% (117/140) at 12 months11
*Patient satisfaction was the secondary endpoint in a multicentre, long-term, prospective, observational, non-interventional study of DEGARELIX FERRING patients in the Netherlands with advanced prostate cancer. The primary endpoint was PFS failure rate.
DEGARELIX FERRING extended licence
Adapted from European Association of Urology Guidelines, 202215
References
1. Drudge-Coates L. Int J Urol Nurs 2009;3(3):85–92.
2. Plummer C, et al. Trends Urol Men’s Health 2017;13–18.
3. Chowdhury S, et al. BJU Int 2013;112(2):182-9.
4. Gandaglia G, et al. Clin Genitourin Cancer 2015;13:e123–e130.
5. Albertsen et al. Eur Urol 2014 Mar;65(3):565-73
6. Hospital Episode Statistics (HES) database. (Data for Jan-Dec 2021).
7. Data on file, Ferring Pharmaceuticals Ltd. Based on HES data, Xiang-Ming et al., 2017, NICE 2011.
8. Klotz L, et al. Eur Urol 2014;66:1101–1108.
9. Crawford ED, et al. Urology 2014;83:1122–1128.
10. Boccon-Gibod L, et al. Ther Adv Urol 2011;3:127–140.
11. Roshani H, et al. Curr Urol 2021;15:204–208.
12. DEGARELIX FERRING 120 mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: https://www.medicines.org.uk/emc/product/6537. Last accessed: June 2024.
13. DEGARELIX FERRING 80 mg injection Summary of Product Characteristics. Ferring Pharmaceuticals Ltd. October 2022. Available at: https://www.medicines.org.uk/emc/product/6535. Last accessed: June 2024.
14. Relugolix Summary of Product Characteristics. Available at: https://www.accord-healthcare-products.co.uk/products/o/orgovyx-tablets. Last accessed: June 2024.
15. EAU – EANM – ESTRO – ESUR – ISUP – SIOG Guidelines on Prostate Cancer, 2022. Available at: https://uroweb.org/guidelines/prostate-cancer. Last accessed: June 2024.
